Tislelizumab

3 articles published between March 2, 2026 and October 1, 2026.

THE DRUG DOCKET

FDA clears tislelizumab plus zanidatamab for HER2-positive gastric cancer

BeiGene's PD-1 antibody, added to the HER2 drug zanidatamab and chemotherapy, lifted median overall survival to 26.4 months from 19.2 in the HERIZON-GEA-01 trial. The gain concentrated in the strongest HER2-expressers.

3 min read

THE DRUG DOCKET

Zanidatamab clears FDA for first-line HER2-positive gastro-oesophageal cancer

In HERIZON-GEA-01, zanidatamab plus chemotherapy raised median progression-free survival to 12.4 months from 8.1 with trastuzumab. A clear survival gain came only when tislelizumab was added.

3 min read

WHAT THE STUDY ACTUALLY SAYS

Immunotherapy added to chemo extended remission in advanced nasopharyngeal cancer

A three-year update of RATIONALE-309 found tislelizumab plus chemotherapy lengthened median progression-free survival to 9.6 months from 7.4. The overall-survival gain was not statistically significant on its own.

3 min read

This page indexes this newspaper’s reporting on Tislelizumab. It is not a medical reference entry, and nothing here is medical advice. See our editorial standards.